TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of a Diuretic Algorithm in Clinical Stability in Heart Failure Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of both genders~* Age ≥ 18 years~* Diagnosed with systolic HF~* Able to monitor body weight at home~* Using furosemide~Exclusion Criteria:~* Those who are not able to make return visits or participate in telephone contact, and those on renal replacement therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: ACTIVE_COMPARATOR): In the control group, patients just diuretic adjusted (Furosemide 40 milligrams) by the doctor on the baseline. The patients do not receive phone calls neither advising on non-pharmacological treatment; The medication is adjusted by the doctor during the initial evaluation of study baseline.
- Furosemide and Phone contact (Type: EXPERIMENTAL): The intervention group is conducted by a nurse in a systematic way during one time per week. If signs and symptoms of congestion, the dose of diuretic ( furosemide ) is revised , nonpharmacological guidelines are provided. According to the algorithm 1KG weight changes are indicative of modifying the diuretic dose , with the addition or reduction 1 tablet a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic spontaneous urticaria (CSU) refractory to H1-antihistamine treatment~* Presence of itch an hives for more than 6 weeks~* UAS7 score of more than 14 (range 0-42)~* Patient has history of insufficient response to 4x of the approved dose of H1-antihistamines~* CSU diagnosis for more than 6 months~* Angioedema at least 4x in the last 6 months~Exclusion Criteria:~* Patients with non urticaria associated angioedema~* History of hypersensitivity to omalizumab or the rescue medication or to drugs of similar chemical structure~* Evidence of parasitic infection~* Previous treatment with omalizumab within the last 6 months prior to screening~* History of anaphylactic shock~* Woman who are pregnant or breast feeding~* Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 Omalizumab (Type: EXPERIMENTAL): omalizumab once a month via subcutaneous injection.
- 2 Placebo (Type: PLACEBO_COMPARATOR): placebo of omalizumab once a month via subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute Effect of Exenatide on Brain Glucose Metabolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males age 18-65 years old~2. Patients must have Body Mass Index (BMI) between 25 and 40 kg/m2~3. 2-hour glucose concentration above 140mg/dl after 75g glucose load, ie, having impaired glucose tolerance or newly diagnosed type 2 diabetes.~4. Patients must have BMI of 25-40 kg/m2~5. Patients must have no known severe liver or kidney disease, cancer, neurologic, psychiatric or systemic disease, ability to understand the study.~6. Only patients whose body weight has been stable (±3-4 pounds) over the three months prior to study will be included.~7. Patients must have the following laboratory values:~   * Hematocrit ≥ 34 vol%~  * Serum creatinine\* ≤ 1.5 mg/dl in males and~  * Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT): ≤ 2.5 times upper limit of normal~  * Alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT): ≤ 2.5 times upper limit of normal~  * Alkaline phosphatase ≤ 2.5 times upper limit of normal~  * If serum creatinine is ≤ 1.5 mg/dl in males, the PI can grant an exception and not exclude the patient if the Glomerular filtration rate (GFR) is \>70 ml/min~Exclusion Criteria:~Patients are excluded from participation in the study if they meet any of the following criteria:~1. Patients with major chronic illness (cancer, liver, kidney, cardiovascular disease)~2. Patients with BMI over 40 and under 25~3. Patient with age below 18 yrs and over 65 yrs~4. Female subjects~5. Patients with type 1 diabetes~6. Patients treated for type 2 diabetes~7. Subjects with normal glucose tolerance (NGT)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide first, then Placebo (Type: EXPERIMENTAL): Exenatide 5mcg was injected subcutaneously 30 min before Oral Glucose Tolerance Test (OGTT)-PET study. The same subject was studied again a few weeks later with the same protocol with Placebo injection.
- Placebo first, then Exenatide (Type: EXPERIMENTAL): Placebo was injected subcutaneously 30 min before OGTT-PET study. The same subject was studied again a few weeks later with the same protocol with injection of Exenatide 5mcg .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a diagnosis of adult-onset Rheumatoid Arthritis (RA) of at least 3 months duration but no longer than 15 years~* Subjects with an active adult Rheumatoid Arthritis disease~* Subjects who have been on Disease-Modifying Anti-Rheumatic Drug (DMARD) therapy for at least 12 weeks~Exclusion Criteria:~* Subject must not have a secondary, non-inflammatory type of musculoskeletal condition (eg, osteoarthritis or fibromyalgia) that in the investigator's opinion is symptomatic enough to interfere with evaluation of the effect of study drug on the subject's primary diagnosis of Rheumatoid Arthritis (RA)~* Subject must not have a diagnosis of any other inflammatory arthritis (eg, psoriatic arthritis or ankylosing spondylitis)~* Subject must not have a history of an infected joint prosthesis at any time with prosthesis still in situ~* Subject must not have received more than 1 biological agent~* Subject must not have a history of lymphoproliferative disorder including lymphoma or signs and symptoms suggestive of lymphoproliferative disease at any time~* Subject with known Tuberculosis (TB) disease, high risk of acquiring TB infection or latent TB infection~* Subject must not have a known hypersensitivity to any components of the investigational medicinal product~* Subject must not have contraindications for Magnetic Resonance Image (MRI) and contrast agent~* Subject must not have any other condition which, in the investigator's judgement, would make them unsuitable for inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo followed by Certolizumab Pegol (CZP) (Type: OTHER): Placebo, saline solution for sc injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
- Certolizumab Pegol (CZP) (Type: EXPERIMENTAL): Certolizumab Pegol (CZP) 400 mg for subcutaneous injection at Weeks 0, 2 and 4 followed by 200 mg 2-weekly from Week 6 to Week 40

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mobile Application for Improving Symptoms and Adherence to Oral Chemotherapy in Patients With Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patient Participant Inclusion Criteria~* Age greater than 18 years~* Diagnosis of cancer with a new or existing prescription for oral chemotherapy~* Receiving cancer care at either Massachusetts General Hospital Cancer Center or community affiliates (North Shore or Emerson Hospitals)~* Eastern Cooperative Oncology Group (ECOG) ranging from 0 (asymptomatic) to 2 (symptomatic and in bed \>50% of the day)~* Able to read and respond to questions in English~* Uses smart mobile phone (either operating system (iOS) \[iPhone\] or Android device)~Clinician Participant Inclusion Criteria - Clinician participants must be oncology clinicians (i.e. physicians and nurse practitioners) who maintain at least 25% clinical practice at the Massachusetts General Hospital Cancer Center or one of its community affiliates at the North Shore or Emerson Hospital.~Stakeholder Participant Inclusion Criteria - Four groups of stakeholders will provide ongoing feedback about the study design, methods, and results. To be eligible as a stakeholder, the participant must be able to represent the interests and perspective of at least one of the following stakeholder groups:~* Oncology Patient or Family Member~* Oncology Clinician (e.g., Physician or Nurse Practitioner)~* Cancer Practice Setting Administrator Health System, Community, and Society.~Exclusion Criteria:~Patient Participant Exclusion Criteria~* Individuals with co-morbid acute or untreated psychiatric symptoms (e.g., psychosis) or neurologic dysfunction will be excluded given that such symptoms would interfere with consent and participation.~* Individuals who own Windows or Blackberry smart mobile phones will not be eligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mobile Application Intervention (Type: EXPERIMENTAL): Participants in the intervention group will receive the mobile application for improving symptoms and adherence to oral chemotherapy along with their standard oncology care. The proposed elements of the mobile application include the following: 1) specification of an oral chemotherapy treatment plan; 2) weekly collection of patient-reported symptoms and medication adherence; and 3) delivery of real-time, tailored feedback to patients as well as immediate transmission of survey results to oncology clinicians.
- Standard Oncology Care (Type: NO_INTERVENTION): Participants in the control group will receive standard oncology care only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between 18 75 years of age, inclusive, at time of informed consent.~* Must have moderate to severe alopecia areata:~Exclusion Criteria:~* History of human immunodeficiency virus (HIV) or positive HIV serology at screening,~* Infected with hepatitis B or hepatitis C viruses.~* Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)~* Have received any of the following treatment regiments specified in the timeframes outlined below:~Within 6 months of first dose of study drug: Any cell depleting agents Within 12 weeks of first dose of study drug: Any studies with JAK inhibitors; Other biologics Within 8 weeks of first dose of study drug: Participation in other studies involving investigational drug(s) Within 6 weeks of first dose of study drug: Have been vaccinated with live or attenuated live vaccine.~Within 4 weeks of first dose of study drug: Use of oral immune suppressants; Phototherapy (NB UVB) or broad band phototherapy; Regular use (more than 2 visits per week) of a tanning booth/parlor.~Within 2 week of first dose of study drug: Topical treatments that could affect AA; Herbal medications with unknown properties or known beneficial effects for AA.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): PF-06651600
- Cohort 2 (Type: EXPERIMENTAL): PF-06700841
- Cohort placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed Informed Consent~2. Verified diagnosis of PSC~3. PSC patients with or without IBD~4. Women of childbearing potential have to apply during the entire duration of the study a highly effective method of birth control.~Exclusion Criteria:~1. History or presence of other concomitant liver diseases~2. Treatment with UDCA within 8 weeks prior to baseline visit.~3. Child B/C liver cirrhosis~4. Total bilirubin \> 3.0 mg/dl at screening or baseline.~5. Any relevant systemic disease~6. TSH\>ULN at screening~7. any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder~8. Any active malignant disease~9. Known intolerance/hypersensitivity to study drug~10. Existing or intended pregnancy of brest feeding~11. Simultaneous participation in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- B (Type: EXPERIMENTAL): norUDCA
- C (Type: EXPERIMENTAL): norUDCA
- placebo (Type: PLACEBO_COMPARATOR): Placebo
- A (Type: EXPERIMENTAL): norUDCA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mucosal Healing Study in Crohn's Disease (CD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients suffering from active Crohn's disease \[Crohn's Disease Activity Index(CDAI) ≥ 220 and ≤ 450\] and at least 2 segments with endoscopic ulcerative lesions with Baseline Crohn's Disease Endoscopic Index of Severity (CDEIS) ≥ 8~* Patients who need to be treated by anti-tumor necrosis factor (anti-TNF) therapy~Exclusion Criteria:~* Obstructive intestinal strictures, bowel resection, proctocolectomy or total colectomy, current total parenteral nutrition, short bowel syndrome~* History of tuberculosis or positive tests for tuberculosis at screening~* All the concomitant diseases or pathological conditions that could interfere with Crohn's disease assessment or to be harmful for the well being of the patient~* Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CDP870 400 mg (Type: EXPERIMENTAL): Certolizumab pegol (CDP870) 400 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Male and femal subjects who~* are 18 to 45 years of age, inclusive, on the day of screening;~* have an understanding of the study, agree to its provisions, and give written informed consent prior to study entry;~* are clinically healthy, as determined by medical history and physical examination;~* agree to keep a daily record of symptoms;~* if female and capable of bearing children, have a negative urine pregnancy test result at study entry and agree to employ adequate birth control measures for the duration of the study.~Exclusion Criteria:~Subjects who~* are at high risk of contracting H5N1 influenza infection (e.g. poultry workers);~* suffer from a significant neurological, cardiac, pulmonary (including asthma), hepatic, rheumatic, autoimmune, hematological or renal disorder;~* are unable to lead an independent life as a result of either physical or mental handicap;~* suffer from any kind of immunodeficiency;~* suffer from a disease or are undergoing a form of treatment that can be expected to influence immune response. Such treatment includes, but is not limited to, systemic or high dose inhaled (\>800µg/day of beclomethasone dipropionate or equivalent) corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs;~* have a history of inflammatory or degenerative neurological disease (e.g. Guillain Barré);~* have a history of severe allergic reactions or anaphylaxis;~* have a rash, dermatologic condition or tattoos which may interfere with injection site reaction rating;~* have received a blood transfusion or immunoglobulins within 90 days of study entry;~* have donated blood or plasma within 30 days of study entry;~* have received any live vaccine within 4 weeks or inactivated vaccine within 2 weeks prior to vaccination in this study;~* have undergone systemic corticoid therapy within 30 days prior to study entry;~* have a functional or surgical asplenia;~* have a known or suspected problem with alcohol or drug abuse;~* were administered an investigational drug within six weeks prior to study entry or are concurrently participating in a clinical study that includes the administration of an investigational product;~* are a member of the team conducting this study or are in a dependent relationship with the study investigator. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the investigator;~* if female, are pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* CMML diagnosis according to WHO criteria~* Stable excess in blood monocytes,\>1x10G/l and \>10% of WBC~* Bone marrow blasts \<20%~* Dysplasia of at least one lineage or clonality marker or blood monocytosis during more than 3 months w/o other explanation~* With:~  * if WBC \< or= 12 000/mm3: IPSS high or intermediate 2~ * if WBC \> 12 000/mm3: at least two of the following criteria: blast cells \> 5% in the bone marrow, clonal cytogenetic abnormality other than t(5;12)(q33;p13), anemia (Hb \< 100 g/l), thrombocytopenia (platelet count \< 100G/l), splenomegaly \> 5 cm below costal margin, extramedullary localization~* Either untreated or previously treated with~* Hydrea or Etoposide given orally~* non intensive chemotherapy~* intensive chemotherapy given more than 3 months before inclusion~* With performance status 0-2 on the ECOG scale~* With estimated life expectancy of at least 12 weeks~* With adequate organ function including the following:~  * Hepatic: total bilirubin \< 1.5 times upper limit of normal (ULN), alanine transaminase (ALT) and aspartate transaminase (AST) \< 3 times ULN~ * Renal: serum creatinine \< 1.5 times ULN, creatinine clearance \> 30 ml/min~* With informed consent~* Negative pregnancy and adequate contraception if relevant~Exclusion Criteria:~* Myeloproliferative/myelodysplastic syndrome other than CMML~* Acute blastic transformation of CMML with bone marrow blasts\>20%~* Patients eligible for allogenic bone marrow transplantation with identified donor~* CMML with t(5;12) or PDGFbetaR rearrangement that could receive Imatinib~* Previous treatment with a hypomethylating agent~* Age \< 18 years old~* Pregnancy or breastfeeding~* Performance status\> 2 on the ECOG Scale~* Estimated life expectancy \< 12 weeks~* Serious concomitant systemic disorder, including active bacterial, fungal or viral infection, that in the opinion of the investigator would compromise the safety of the patient and/or his/her ability to complete the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decitabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete